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Glycogen storage disease type I (GSDI), an inborn error of carbohydrate metabolism, is caused by defects in the
glucose-6-transporter/glucose-6-phosphatase complex, which is essential in glucose homeostasis. Two types exist,
GSDIa and GSDIb, each caused by different defects in the complex. GSDIa is characterized by fasting intolerance
and subsequent metabolic derangements. In addition to these clinical manifestations, patients with GSDIb suffer
from neutropenia with neutrophil dysfunction and inflammatory bowel disease.
With the feasibility of novel cell-based therapies, including hepatocyte transplantations and liver stem cell
transplantations, it is essential to consider long term outcomes of liver replacement therapy. We reviewed all GSDI
patients with liver transplantation identified in literature and through personal communication with treating physicians.
Our review shows that all 80 GSDI patients showed improved metabolic control and normal fasting tolerance after liver
transplantation. Although some complications might be caused by disease progression, most complications seemed
related to the liver transplantation procedure and subsequent immune suppression. These results highlight the potential
of other therapeutic strategies, like cell-based therapies for liver replacement, which are expected to normalize liver
function with a lower risk of complications of the procedure and immune suppression.Introduction
Glycogen storage disease type I (GSDI) is an autosomal
recessive inborn error of carbohydrate metabolism
caused by defects in the glucose-6-phosphate transporter
(G6PT)/glucose-6-phosphatase (G6Pase) complex [1,2].
G6PT/G6Pase complex plays a crucial role in interpran-
dial glucose homeostasis and consists of a catalytic sub-
unit, glucose-6-phosphatase-α (G6Pase-α) encoded by
the G6PC gene and a glucose-6-phosphatase transporter
(G6PT), encoded by the SLC37A4 gene. Deficient activ-
ity of G6Pase-α causes GSDIa [3] and deficient activity
of G6PT causes GSDIb [4]. GSDI is a relatively rare dis-
order with an incidence of 1:100.000, represented in 80%
of the patients by GSDIa and in 20% by GSDIb [5].
G6Pase catalyzes the final step in glycogenolysis and in
gluconeogenesis in the lumen of the endoplasmic reticulum
in primarily liver, but also kidney and intestine, by hy-
drolyzation of glucose-6-phosphate (G6P) to glucose
and inorganic phosphate. Because G6Pase affects both gly-
cogenolysis and gluconeogenesis, inactivating mutations* Correspondence: S.Fuchs@umcutrecht.nl
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duced fasting tolerance. Clinical complications in patients
include hepatomegaly, nephromegaly, hypoglycemia, hyper-
lipidemia, hyperuricemia, lactic acidemia, and growth re-
tardation [5]. In addition to the clinical manifestations in
GSDIa, patients with GSDIb generally also suffer from neu-
tropenia, impaired neutrophil function and inflammatory
bowel disease.
Prevention of hypoglycemia is crucial in the treatment
of GSDI [5]. This is achieved by frequent feedings during
day and night or nocturnal gastric drip feeding. Any feed-
ing problem can result in a hypoglycemic event, with risk
of cognitive impairment, seizures and finally death. This
represents a constant threat for patients and their parents,
severely affecting quality of life.
Despite progress in the treatment of GSDI, metabolic
control remains challenging and hepatic, renal and/or im-
munologic complications may arise. Because of the prom-
inent hepatic manifestations in GSDI, orthotopic liver
transplantations have been performed [5]. Short-term out-
come of liver transplantation for GSDI is encouraging, but
very few papers report long-term follow-up. With the ad-
vent of less invasive cell-based therapies, including hepato-
cyte transplantations and liver stem cell transplantations,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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with GSDI, it is eminent to know the long-term outcomes
of liver specific therapies. We therefore reviewed short-
term and long-term outcomes of liver transplantations in
GSDIa and GSDIb patients.
Methodology
English-language literature was systematically reviewed
through searches in PubMed and in the references of
relevant publications to find all GSDIa and GSDIb liver
transplantations published in literature. Through per-
sonal communication with treating physicians, we com-
pleted information and identified additional cases.
Results
We identified 58 patients with GSDIa who underwent a
liver transplantation between 1982 and 2012 (Table 1,
Additional file 1: Table S1); 3 of these patients received
a second liver transplantation. The average age at trans-
plantation was 20 years (range: 4.3-50 years). A living-
related transplantation was performed in 16 cases. 6
Patients underwent a combined liver-kidney trans-
plantation (Table 2). The immunosuppressive regime
consisted of steroids, combined with cyclosporine in
12 patients, with cyclosporine and azathioprine in 17
patients and with tacrolimus in 9 patients. The specific
immunosuppressant medication was not reported in
22 cases (Table 1).
The indication for liver transplantation varied and in-
cluded hepatic adenomas/liver abnormalities/focal nodular
hyperplasia (29 patients), poor metabolic control (27 pa-
tients), growth retardation (13 patients, some with delayed
puberty and sexual maturation), renal failure (5 patients, 3
of whom received a combined liver-kidney transplantation),
bleeding complications leading to anemia (1 patient)
and acute pancreatitis due to severe hypertriglyceridemia
(1 patient).
4 Patients with GSDIa died; 1 due to rejection related
liver failure (15 years after 1st liver transplantation, 1 year
after 2nd liver transplantation with combined kidney
transplantation), 1 committed suicide 3 years post-
transplantation, 1 because of metastatic hepatocellular
carcinoma 4 months after transplantation, and 1 because
of pancreatitis and sepsis 2 months post-transplantation.
All other patients were alive at time of follow-up (range
several months to 11.3 years post-transplantation). In all
cases, liver function was good and metabolic control
normalized, without a specific dietary regime. In 13
cases, catch-up growth was mentioned (Table 3). The
patients with catch-up growth reported were all chil-
dren or teenagers and for 2 of these, sexual matur-
ation was also reported. In addition, one patient of
27 years old showed an increase of 5.4 cm in height
2 years after transplantation.The complication reported most frequently was acute
or chronic renal failure. Acute renal failure occurred in
8 patients, including 1 patient with pre-transplantation
renal failure. One of these 8 patients required tempor-
ary dialysis. Chronic renal failure was seen in 6 patients
after transplantation and 2 of these patients required dialy-
sis. In addition, 1 case of gouty arthritis was reported 4
years post-transplantation. It is unclear whether this was
due to renal failure. None of the patients who had received
a combined liver-kidney transplantation developed renal
failure.
Transplantation associated complications were seen in
18/58 patients and included hepatic artery thrombosis (2
patients), late portal vein thrombosis (2 patients), hepatic
vein obstruction (2 patients), prolonged drainage (2 pa-
tients), acute (steroid responsive) rejection (5 patients),
chronic rejection (3 patients) and a never functioning liver
transplant (2 patients). Complications that might have been
caused by immune suppression included hypertension
(4 patients), starting one month after transplantation and
reversible insulin-dependent diabetes (3 patients), starting
within the first week after transplantation (Table 4). In
addition, various infections were reported (5 with cyto-
megalovirus 1 month after transplantation and 1 patient
with hepatitis 4 years after transplantation).
Liver transplantation was performed in 22 patients with
GSDIb between 1991 and 2012, at an average age of 10
years (range 1–44 years) (Table 1, Additional file 1:
Table S2). One patient had a kidney transplantation 2
years prior to the liver transplantation, with good func-
tion of both grafts reported 8 months after liver trans-
plantation (Table 2). Indications for liver transplantation
in GSDIb patients included poor metabolic control (21 pa-
tients) and/or recurrent infections (10 patients), growth
retardation (3 patients), and oral and anal ulcera (1 pa-
tient). Immune suppression after transplantation involved
cyclosporine in 1 patient and tacrolimus in 16 patients.
The immune suppressive medication wat not reported in
the other 6 patients.
At follow-up, 1 patient had died 1.4 months after trans-
plantation, due to systemic candidiasis. In all patients,
metabolic abnormalities were corrected by transplantation.
Catch-up growth was reported in 2 cases (Table 3). In 14
patients, neutropenia improved, while in 7 patients neutro-
penia persisted. One report mentioned prolonged bleeding
time and bruises after several years. 7 Patients had trans-
plantation associated complications, including anemia in
the first days after the transplantation (1 patient) and vari-
ous infectious diseases shortly after transplantation (6 pa-
tients). Complications potentially associated with immune
suppressive therapy included 1 patient with hepatitis B,
seven months after transplantation, and 1 patient with cyto-
megalovirus infection several years after transplantation
(Table 4). 1 patient developed tacrolimus encephalopathy
Table 1 Indication and follow-up of GSDIa and GSDIb liver transplantation
GSDIa (n = 58) GSDIb (n = 22)
Year of transplantation 1982 – 2012 1991 – 2012
Indications
Hepatic adenomas or liver abnormalities
(mostly focal nodular hyperplasia)
29 [6-22]
Poor metabolic control 27 [6,8-10,14-16,19,21,23-27] 21 [13,28-34]
Growth retardation 13 [10,14-16,23,24,27] 3 [32,33,35]
Recurrent infections 10 [28,33,34]
Renal failure 5 [36]
-Of which also kidney transplant 3 [17,26,37]
Bleeding complications (anemia) 1 [27]
Pancreatitis 1 [24]
Anal and oral ulcera 1 [30]
Immunosuppressive regime
Cyclosporine 12 [6,7,9,10,12,14,15,17,21,26] 1 [28]
Cyclosporine + azathioprine 17 [16,23,25,38,39] -
Tacrolimus 9 [16,18,21,36] 16 [30,31,33-35]
Not reported 22 6
Outcome and complications GSDIa Short-term (≤1 year) Long-term (>1 year)
Normalization liver function 58 (all) -
Catch-up growth - 13 [10,13,14,23,25,39]
Sexual maturation - 2 [25]
Re-OLT 2 [16,23] 1 [20]
Death 1 (pancreatitis and sepsis) [25] 3 (rejection related liver failure, suicide,
metastatic hepatocellular carcinoma) [19], PC
Renal failure 6 [21] 4 [20]
-Of which already pre-transplant 1 [39]
-Requiring dialysis 1 [12] (temporary) 2 [27], PC (permanent)
-Gouty arthritis (due to renal failure?) - 1 [14]
Metastatic hepatocellular carcinoma 1PC
Transplantation associated
-Hepatic artery thrombosis 2 [16,23] -
-Portal vein thrombosis - 2 [6,16]
-Hepatic vein obstruction 2 [25] -
-Prolonged drainage 2 [25,39] -
-Rejection 5 [14,20,21,38,39] 3 [6,9]
-Never functioning liver after transplantation 2 [23,24]
Therapy (immune suppression) associated
-Hypertension 4 [25,39] -
-Insulin-dependent diabetes (reversible) 3 [8,9,21] -
-Infections (CMV, hepatitis) 7 [21,25,39] 1 [14]
Outcome and complications GSDIb Short-term (≤1 year) Long-term (>1 year)
Normalization liver function 23 (all)
Catch-up growth 2 [32]
Death 1 (systemic candidiasis) [40]
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Table 1 Indication and follow-up of GSDIa and GSDIb liver transplantation (Continued)
Neutropenia -




-Infection 6 [34] -
-Anemia 1 [33] -
-Rejection - 1 [13]
Therapy (immune suppression) associated
-Infection 1 [30] 1 [26]
-Tacrolimus encephalopathy 1 [35]
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drawal of tacrolimus. None of the reports described renal
complications.
Discussion
In this review, we show that liver transplantations sustain-
ably corrected fasting tolerance and the induced metabolic
abnormalities associated with GSDIa and GSDIb, thereby
immensely improving quality of life for patients. In
addition, catch-up growth was seen in most patients with
growth retardation (13/13 (100%) and 2/3 (67%) in GSDIa
and GSDIb patients, respectively).
The extra-hepatic symptoms of the disease might
however persist after liver transplantation. In GSDIa pa-
tients, renal failure was the most common complication
(14/58 (24%) of patients) and 3/14 (21%) required dialy-
sis. The natural course of renal function in GSDI pa-
tients shows a biphasic pattern [41]. We identified only
1 patient with both pre- and post-transplantation renal
failure; renal function was restored in the other 4 patients
with pre-transplantation renal dysfunction. Notably, 3 of
these 4 patients had received a combined liver-kidney
transplantation. In the other patients, renal dysfunction
developed after transplantation. It is yet unclear whether
post-transplantation renal failure in GSDIa represents pro-
gression of the disease, a secondary reaction to poor meta-
bolic control, toxicity from immune suppressive medication
after liver transplantation, or a combination. Strikingly,Table 2 Follow-up of combined liver-kidney transplantation
Combined liver-kidney
transplantation
Year of transplantation [ref] Age at
transplantation
GSDIa 1996 (2nd OLT and KT) [20] 30
1996 [37] 34
2000 [26] 19.5
2004 (publication) [17] 25
2011 (publication) [36] 30
GSDIb 2003 (2y later OLT) [33] 32none of the GSDIb patients developed renal failure. We are
unaware of a pathophysiological mechanism to explain why
GSDIa patients would be more prone to develop renal fail-
ure than GSDIb patients, nor has this been observed in our
experience with GSDI patients. Potentially, this is a coinci-
dental finding due to the relatively small number of patients
evaluated.
In GSDIb patients, persistent neutropenia was the most
important complication (7/22 (32%) of patients). Neutro-
penia in GSDIb has recently been attributed to a second
G6P hydrolase, called G6Pase-β [42]. The G6PT/G6Pase-
β complex maintains glucose homeostasis and function in
neutrophils. Deficiency of the G6PT/G6Pase-β complex in
neutrophils leads to impaired endogenous glucose produc-
tion and enhanced endoplasmic reticulum stress, oxidative
stress and apoptosis, leading to neutropenia [42]. Migra-
tion of neutrophils from the blood to inflamed tissues (e.g.
intestines, liver adenoma) might further contribute to the
neutropenia [43]. It remains unclear why neutropenia im-
proves after liver replacement in some patients and per-
sists in others. It is possible that improved metabolic
control and general well-being result in decreased inflam-
mation, leading to higher blood neutrophil concentrations.
Second, immediate increase in neutrophil count after liver
transplantation might be related to the neutrophilic effect
of steroid therapy. However, recurrence of neutropenia
after steroid tapering has not been reported. Finally, host/
donor bone marrow chimerism has been observed afterCurrent age
(if alive)
Outcome and complications
† 1.3 years: PT died at age 31
52 4.1 years: alive
34 2 years: normal liver and kidney function
35 4 months: normal liver and kidney function
33 7 months: good condition, both grafts functional
41 8 months: good liver function and normal kidney function
Table 3 Follow-up of catch-up growth
Catch-up growth Year of transplantation [ref] Age at transplantation Current age (if alive) Catch-up growth
GSDIa 1986 [23] 6 34 2 years: catch-up growth
1987 [10] 27 54 2 years: catch-up growth (5.4 cm)
1993 [13] 11.8 33 Yes: time of follow-up not mentioned
Between June 1994 and
December 2005 [25]
median 7.3 (n = 4) Unknown The mean height-for-age
increased from <10th percentile
(at t = 0) to 50th percentile at 5 years
Between 1996 and 2001 [39] 4.3-14.5 (n = 4) 20-30 2 years: catch-up growth
1999 (publication) [14] 15 30 8 years: catch-up length growth
(−6SD to −1.5SD)
1999 (publication) [14] 17 32 6 years: catch-up length growth
(−2.5SD to −1.5SD)
GSDIb 2004 (publication) [32] 8 18 Yes: time of follow-up not mentioned
2004 (publication) [32] 11.1 21 Yes: time of follow-up not mentioned
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transplanted with the liver graft, can migrate into the recip-
ient’s immune system and bone marrow. This phenomenon
may result in both long-term tolerance induction and
induction of enzymatic activity in extra-hepatic tissue.
Clearly, although the molecular mechanism causing con-
genital neutropenia in GSDIb has now been elucidated,
many aspects of the phenotype remain poorly understood.
Our review shows that there are still many complica-
tions related to the liver transplantation procedure (18/58
(31%) in GSDIa and 8/22 (36%) in GSDIb patients), as well
as complications suspected to be related to immune sup-
pressive therapy (13/58 (22%) in GSDIa and 3/22 (14%) in
GSDIb patients). In the light of these complications, novel
therapeutic strategies, like hepatocyte and liver stem cell
transplantations might represent attractive alternatives
for liver transplantation in GSDI patients. Liver (stem)
cells can be infused through the portal vein, which is con-
siderably less invasive than liver transplantation and hence
not associated with surgery related complications. We
identified 3 GSDIa and GSDIb patients, treated withTable 4 Follow-up of therapy-associated complications
Therapy-associated complications Therapy-associated complic
GSDIa Diabetes (n = 3)
Hypertension (n = 4)
Infection (n = 8)
GSDIb Infection (n = 32)
Encephalitishepatocyte transplantations (Additional file 1: Table S3,
Additional file 1: Table S4). Normalization of metabolic
parameters was observed in all patients after transplant-
ation and no therapy-related complications were men-
tioned. This concurs with previously reported beneficial
effects from human hepatocyte transplantations for dif-
ferent hepatic indications (metabolic, acute and chronic
liver failure) [45]. However, these beneficial effects were
short-lived and effects subsided within months. Similarly,
metabolic improvement decreased in one of the GSDI pa-
tients treated with hepatocytes after 3 years and eventually
subsided completely [46]. Nevertheless, these case reports
show that cell-based therapies can restore liver function for
at least a limited period, which might be beneficial in acute
situations awaiting a liver transplantation.
Liver stem cell transplantations might provide additional
advantages. Stem cells are highly proliferative and have
the potential to bypass the current shortage of donor livers
by expansion in vitro or in vivo upon engraftment. Fur-
thermore, liver stem cell transplantations might require
less immune suppression. For allograft survival after solidation Follow-up time [ref]
-Acute: diabetes mellitus (1 patient) [9,21]
−2 days: insulin-dependent diabetes (1 patient) [9]
−3 days: for following 5 days insulin pump (1 patient) [8]
−1 month: 4 patients, 2 received short term treatment
with antihypertensive medication [25,39]
-Acute: CMV (2 patients) [21]
−1 month: CMV (5 patients) [25,36,39]
−4 years: hepatitis C (1 patient) [14]
−7 months: hepatitis B (1 patients) [30]
−6.2 years: CMV (1 patient) [20]
-Acute: tacrolimus encephalitis (1 patient) [35]
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suppression, with serious associated side effects, including
toxicity, malignancy development and infectious complica-
tions. Human fetal-liver derived hepatocytes have been
given for end-stage decompensated liver cirrhosis without
immune suppression, based on the concept that fetal cells
do not express HLA yet [47]. Short term outcomes were
promising, but long term follow up has not been reported.
This illustrates that progenitor cell-based therapies might
be given without or with reduced immune suppression. In
this context, autologous transplantation with genetically
corrected stem cells [48,49] and hepatocyte-like cells gen-
erated from autologous induced pluripotent stem cells [50]
have exciting potential for the future.
Despite promising, some complications might still occur
after stem cell based therapies, including renal complica-
tions. New-born G6PC knock-out mice treated with bone
marrow-derived myelomonocytic cells displayed restored
G6Pase activity and improved liver functional parameters,
without amelioration of renal involvement [51]. Similarly,
there is concern that hepatic adenoma and carcinoma
might develop in the cells with a defect G6PT/G6Pase
complex with the use of cell-based therapies that do not
replace all patient cells. However, a recent study has dem-
onstrated that the occurrence of hepatocellular adenoma
was prevented by gene therapy in G6pc−/− mice, despite
partial and variable G6Pase activity, but with normalized
blood metabolite profiles and glucose tolerance [52]. This
concurs with the observation that development of hepato-
cellular adenoma and carcinoma appears to be related to
the degree of steatosis and has been shown to regress with
improved metabolic control [53], as is expected from cell-
based therapies.
In conclusion, all GSDI patients reviewed in this art-
icle showed improved metabolic control and normal
fasting tolerance after liver transplantation. This dra-
matically improved the quality of life of these patients,
but a substantial number of patients experienced compli-
cations. Although some complications might be caused by
disease progression, most seemed related to the liver
transplantation procedure and subsequent immune sup-
pression. These complications underscore the need for
improvement of therapeutic strategies and emphasize the
potential of novel (stem) cell-based treatments.Additional file
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